Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
4.170
-0.050 (-1.18%)
At close: Jun 12, 2026, 4:00 PM EDT
4.250
+0.080 (1.92%)
After-hours: Jun 12, 2026, 7:10 PM EDT
Alvotech Revenue
Alvotech had revenue of $105.87M in the quarter ending March 31, 2026, a decrease of -20.29%. This brings the company's revenue in the last twelve months to $559.38M, down -4.48% year-over-year. In the year 2025, Alvotech had annual revenue of $586.32M with 19.74% growth.
Revenue (ttm)
$559.38M
Revenue Growth
-4.48%
P/S Ratio
2.32
Revenue / Employee
$439,439
Employees
1,279
Market Cap
1.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 586.32M | 96.64M | 19.74% |
| Dec 31, 2024 | 489.68M | 398.25M | 435.56% |
| Dec 31, 2023 | 91.43M | 6.41M | 7.54% |
| Dec 31, 2022 | 85.03M | 48.26M | 131.23% |
| Dec 31, 2021 | 36.77M | -29.84M | -44.80% |
| Dec 31, 2020 | 66.62M | 34.70M | 108.71% |
| Dec 31, 2019 | 31.92M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.53B |
| Perrigo Company | 4.18B |
| Phibro Animal Health | 1.50B |
| ANI Pharmaceuticals | 923.71M |
| Evotec SE | 859.03M |
| Collegium Pharmaceutical | 796.33M |
| Pacira BioSciences | 734.86M |
| Xeris Biopharma Holdings | 314.85M |
ALVO News
- 4 days ago - Transactions of Managers and Closely Associated Persons - GlobeNewsWire
- 4 days ago - Alvotech Transcript: UBS Virtual Generics and Biosimilars Day - Transcripts
- 6 days ago - Alvotech Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 6 days ago - Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio® - GlobeNewsWire
- 10 days ago - Alvotech Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 10 days ago - Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea® - GlobeNewsWire
- 11 days ago - Main Results of 2026 Annual and Extraordinary General Meeting - GlobeNewsWire
- 12 days ago - Alvotech to present at upcoming investor conferences in June - GlobeNewsWire